Table 2 Changes in efficacy measures

Outcome measurements

GDF-15 (pg/mL)

Baseline

1188 (918 to 1720)

1299 (952 to 1823)

At 12 weeks

1394 (970 to 1942)

1271 (879 to 1872)

Change over 12 weeks

124 (– 27 to 297)

12 (– 87 to 156)

Adjusted between group treatment effect^a

1.09 (1.03 to 1.15)

hsCRP (mg/L)

Baseline

1.82 (0.96 to 3.70)

1.24 (0.66 to 3.40)

At 12 weeks

2.00 (1.13 to 3.50)

1.43 (0.83 to 3.05)

Change over 12 weeks

0.20 (– 0.30 to 1.20)

0.05 (– 0.50 to 0.50)

Adjusted between group treatment effect^a

1.09 (0.86 to 1.38)

hsTNT (ng/L)

Baseline

12.90 (10.10 to 18.30)

14.20 (9.22 to 19.00)

At 12 weeks

13.40 (9.79 to 17.60)

13.10 (9.25 to 17.90)

Change over 12 weeks

0.33 (– 0.90 to 1.00)

– 0.10 (– 1.26 to 1.03)

Adjusted between group treatment effect^a

1.07 (0.98 to 1.19)

Related measurements

Cardiac

LVESV (mL)

Baseline

108.09 (52.04)

102.43 (45.05)

At 12 weeks

99.98 (45.52)

101.90 (44.55)

Change over 12 weeks

– 8.50 (26.45)

0.01 (31.32)

Adjusted between group treatment effect

– 8.79 (– 17.39 to – 0.19)

Metabolic

BMI (kg/m²)

Baseline

28.94 (26.48 to 32.42)

28.27 (25.86 to 32.96)

At 12 weeks

28.68 (26.28 to 31.97)

28.78 (26.04 to 32.64)

Change over 12 weeks

– 0.33 (– 0.69 to – 0.03)

0.15 (− 0.35 to 0.48)

Adjusted between group treatment effect^a

– 0.37 (– 0.57 to – 0.18)

Renal

Plasma volume (mL)

Baseline

3032.59 (404.59)

3175.05 (456.44)

At 12 weeks

2897.51 (383.44)

3177.65 (415.58)

Change over 12 weeks

– 135.08 (135.69)

7.7 (144.25)

Adjusted between group treatment effect

– 115.04 (– 152.15 to – 77.93)